Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01892293 · ClinicalTrials.gov registry record · Phase 1
CT Antigen TCR-Engineered T Cells for Myeloma
A Phase 1 study, sponsored by Adaptimmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01892293: Clinical Trial Phase 1 study, sponsored by Adaptimmune.
NCT01892293 is a Phase 1 study that was terminated before completion, run by Adaptimmune. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01892293, a Phase 1 study, was terminated before completion, sponsored by Adaptimmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will enroll patients with multiple myeloma who have received prior therapy for their disease but their disease has progressed or relapsed.
Primary Outcome
Number of Participants with NCI CTCAE Version 4.0 Adverse Events related to study treatment greater than or equal to Grade 3
Interventions
- DRUG Treatment with NY-ESO-1c259-modified T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-10-15 |
| Est. Completion | 2018-04-09 |
| Phase | Phase 1 |
Why NCT01892293 stopped before completion
NCT01892293 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Treatment with NY-ESO-1c259-modified T cells is the first listed.
NCT01892293 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01892293 about?
NCT01892293 is a clinical study titled "CT Antigen TCR-Engineered T Cells for Myeloma". This study will enroll patients with multiple myeloma who have received prior therapy for their disease but their disease has progressed or relapsed.
What is the current status of trial NCT01892293?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2013-10-15. Estimated completion is 2018-04-09.
What interventions are being tested in trial NCT01892293?
The interventions under investigation include: Treatment with NY-ESO-1c259-modified T cells (DRUG).
Who is sponsoring clinical trial NCT01892293?
This trial is sponsored by Adaptimmune, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01892293's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI